Impact of rheumatoid arthritis, seropositivity and disease-modifying anti-rheumatic drugs on mortality risk in bronchiectasis
The presence of RA doubles the mortality risk in patients with bronchiectasis. Increased mortality risk was more evident in patients with SPRA and those who use DMARDs. Causality cannot be ascertained, but these data suggest that rheumatic inflammation may affect disease progression and excess mortality in patients with BROS.
Authors
- Dong Wook Shin (ORCID: https://orcid.org/0000-0002-1262-2566)
- Anthony De Soyza (ORCID: https://orcid.org/0000-0002-8566-0344)
- Hayoung Choi (ORCID: https://orcid.org/0000-0003-4812-0653)
- Jin‐Hyung Jung (ORCID: https://orcid.org/0000-0002-8920-8777)
- Hyung‐Jin Kim (ORCID: https://orcid.org/0000-0003-3576-3625)
- Hyun Jung Lee (ORCID: https://orcid.org/0000-0002-1269-0913)
- Kyung‐Do Han (ORCID: https://orcid.org/0000-0003-2718-4308)
Institutions
- Soongsil University (KR)
- Samsung (South Korea) (KR)
- Samsung Medical Center (KR)
- Hallym University Kangnam Sacred Heart Hospital (KR)
- NIHR Newcastle Biomedical Research Centre (GB)
- Hanyang University (KR)
- Sungkyunkwan University (KR)
- Newcastle University (GB)
Publication Details
- Journal
- Therapeutic Advances in Respiratory Disease
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1177/17534666251360071
- Citations
- 1
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Ministry of Education